Pre-exposure Option for Reducing HIV in the UK.(PROUD) (PROUD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02065986 |
Recruitment Status :
Completed
First Posted : February 19, 2014
Last Update Posted : January 5, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is looking at a new way to reduce the risk of catching HIV - Truvada-PrEP.
To find out whether a daily tablet, Truvada, can safely reduce the risk of gay men catching HIV, we need to do a large trial in which half the men do not receive Truvada for one year. We do not know if gay men at risk of HIV are interested in taking Truvada, and if they are, whether they would be willing to wait a year before they can take it. The reason it may not be safe, is that taking Truvada-PrEP may lead to an increase in risk behaviour. This could mean there was more chance of catching HIV and other infections.
As well as finding out if a large trial would be possible, this study will looks at other factors including:
- Whether people using PrEP change the number of partners they have sex with
- Whether people using PrEP change how often they use condoms
- Whether PrEP leads to higher rates of other sexually transmitted infections (STIs).
This information on changes in sexual activity over time is one of the most important aspects of the study, because we have never collected this before in the UK. This means we don't know what happens to people's sexual activity without PrEP! In October 2014 an interim analysis of the PROUD study data showed that pre-exposure prophylaxis (PrEP) was highly protective against HIV for gay men and other men who have sex with men (MSM) at high risk of infection. The PROUD Trial Steering Committee announced that participants on the deferred arm of the study, who had not yet started PrEP, should be offered the opportunity to begin PrEP ahead of schedule. As a result, we changed the study design and offered all enrolled participants the opportunity to access PrEP. All study participants will be followed up until study closure in October 2016
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV | Drug: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 544 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD) |
Study Start Date : | October 2012 |
Actual Primary Completion Date : | November 2014 |
Actual Study Completion Date : | October 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm A: Immediate offer of Truvada-PrEP
Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
|
Drug: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC) |
Arm B: Deferred (12m) offer of Truvada-PrEP
Access to Truvada from 12 months after enrolment
|
Drug: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC) |
- Time to accrual of 500 participants and Retention at 12 and 24 months from randomisation [ Time Frame: 2 years ]
- HIV infections acquired between trial entry and 12 months, and between 12 and 24 months [ Time Frame: 24months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Born to male gender, age 18 years or more
- Previously attended the enrolling clinic on at least one occasion
- Completed a screen for HIV and STIs
- HIV negative by a routinely used assay within 4 weeks prior to or on the day of randomisation
- Reported unprotected anal intercourse (UAI) on more than one occasion within the 90 days prior to randomisation
- Likely, in the opinion of the volunteer, to have UAI in the next 90 days
- Willing and able to comply with the visit schedule throughout the follow-up period
- Willing and able to provide written informed consent
Exclusion Criteria:
- An acute viral illness that could be due to HIV seroconversion
- Any contraindications to Truvada according to the current package insert
- Treatment for hepatitis B infection indicated or ongoing
- Unlikely, in the opinion of the clinician, to comply with the randomised allocation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02065986
United Kingdom | |
MRC Clinical Trials Unit | |
London, United Kingdom, WC2B 6NH |
Responsible Party: | MRC [ycm], Medical Research Council |
ClinicalTrials.gov Identifier: | NCT02065986 |
Other Study ID Numbers: |
2012-002373-56 |
First Posted: | February 19, 2014 Key Record Dates |
Last Update Posted: | January 5, 2017 |
Last Verified: | January 2017 |
HIV Prevention Truvada |
Tenofovir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors |
Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents |